Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Achieving the unimaginable: Health equity in haemophilia.

Skinner MW, Nugent D, Wilton P, O'Mahony B, Dolan G, O'Hara J, Berntorp E.

Haemophilia. 2020 Jan;26(1):17-24. doi: 10.1111/hae.13862. Epub 2019 Nov 13. Review.

PMID:
31724316
2.

How to discuss gene therapy for haemophilia? A patient and physician perspective.

Miesbach W, O'Mahony B, Key NS, Makris M.

Haemophilia. 2019 Jul;25(4):545-557. doi: 10.1111/hae.13769. Epub 2019 May 21. Review.

3.

Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study.

Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A.

Haemophilia. 2019 May;25(3):365-372. doi: 10.1111/hae.13703. Epub 2019 Mar 12.

PMID:
30861270
4.

Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains.

Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A.

Haemophilia. 2019 Jan;25(1):75-83. doi: 10.1111/hae.13649. Epub 2018 Dec 6.

PMID:
30520534
5.

Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire.

Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther M, Iorio A.

BMJ Open. 2018 Aug 8;8(8):e021900. doi: 10.1136/bmjopen-2018-021900.

6.

Real-world comparative analysis of bleeding complications and health-related quality of life in patients with haemophilia A and haemophilia B.

Booth J, Oladapo A, Walsh S, O'Hara J, Carroll L, Garcia Diego DA, O'Mahony B.

Haemophilia. 2018 Sep;24(5):e322-e327. doi: 10.1111/hae.13596. Epub 2018 Aug 9.

PMID:
30091822
7.

Value of prophylaxis vs on-demand treatment: Application of a value framework in hemophilia.

Nugent D, O'Mahony B, Dolan G; International Haemophilia Access Strategy Council.

Haemophilia. 2018 Sep;24(5):755-765. doi: 10.1111/hae.13589. Epub 2018 Aug 8.

PMID:
30088692
8.

European principles of inhibitor management in patients with haemophilia.

Giangrande PLF, Hermans C, O'Mahony B, de Kleijn P, Bedford M, Batorova A, Blatný J, Jansone K; European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EAHAD).

Orphanet J Rare Dis. 2018 Apr 27;13(1):66. doi: 10.1186/s13023-018-0800-z. Review.

9.

Patient-centred value framework for haemophilia.

O'Mahony B, Dolan G, Nugent D, Goodman C; International Haemophilia Access Strategy Council.

Haemophilia. 2018 Nov;24(6):873-879. doi: 10.1111/hae.13456. Epub 2018 Apr 6.

PMID:
29626368
10.

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia.

Skinner MW, Chai-Adisaksopha C, Curtis R, Frick N, Nichol M, Noone D, O'Mahony B, Page D, Stonebraker JS, Iorio A.

Pilot Feasibility Stud. 2018 Feb 27;4:58. doi: 10.1186/s40814-018-0253-0. eCollection 2018.

11.

Establishing the appropriate primary endpoint in haemophilia gene therapy pivotal studies.

Pierce GF, Ragni MV, van den Berg HM, Weill A, O'Mahony B, Skinner MW, Pipe SW.

Haemophilia. 2017 Sep;23(5):643-644. doi: 10.1111/hae.13313. Epub 2017 Aug 17. No abstract available.

PMID:
28833947
12.

Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era.

Murphy N, O'Mahony B, Flanagan P, Noone D, White B, Bergin C, Norris S, Thornton L; National Hepatitis C Database Scientific and Technical Committee.

Haemophilia. 2017 Sep;23(5):712-720. doi: 10.1111/hae.13244. Epub 2017 Jul 27.

PMID:
28752601
13.

Kreuth IV: European consensus proposals for treatment of haemophilia with coagulation factor concentrates.

Giangrande PLF, Peyvandi F, O'Mahony B, Behr-Gross ME, Hilger A, Schramm W, Mannucci PM.

Haemophilia. 2017 May;23(3):370-375. doi: 10.1111/hae.13211. Epub 2017 Apr 12.

14.

The first Team Haemophilia Education meeting, 2015, Amsterdam, The Netherlands.

Berntorp E, Hart D, Mancuso ME, d'Oiron R, Perry D, O'Mahony B, Kaczmarek R, Crato M, Pasi J, Miners A, Carlsson KS, Kitchen S, Boehlen F, Giangrande P, Cebura E, Uitslager N, Osooli M, Janeckova D, Haldon R, Rivolta GF.

Eur J Haematol. 2016 Jul;97 Suppl 83:3-18. doi: 10.1111/ejh.12760. Erratum in: Eur J Haematol. 2016 Dec;97(6):594.

PMID:
27272000
15.

Assessments of outcome in haemophilia - a patient perspective.

O'Mahony B, Skinner MW, Noone D, Page D, O'Hara J.

Haemophilia. 2016 May;22(3):e208-9. doi: 10.1111/hae.12922. Epub 2016 Mar 14. No abstract available.

PMID:
26988632
16.

Managing Haemophilia for Life: 5th Haemophilia Global Summit.

Hermans C, Dolan G, Jennings I, Windyga J, Lobet S, Rodríguez-Merchán EC, Di Minno MN, Jiménez-Yuste V, O'Mahony B.

Eur J Haematol. 2015 Oct;95 Suppl 78:1-25. doi: 10.1111/ejh.12617.

PMID:
26350039
17.

Improving haemophilia patient care through sharing best practice.

de Moerloose P, Arnberg D, O'Mahony B, Colvin B.

Eur J Haematol. 2015 Oct;95 Suppl 79:1-8. doi: 10.1111/ejh.12630.

PMID:
26338268
18.

Issues in assessing products for the treatment of hemophilia - the intersection between efficacy, economics, and ethics.

Farrugia A, Noone D, Schlenkrich U, Schlenkrich S, O'Mahony B, Cassar J.

J Blood Med. 2015 Jun 15;6:185-95. doi: 10.2147/JBM.S79091. eCollection 2015.

19.

Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries.

O'Mahony B, Noone D, Prihodova L.

Haemophilia. 2015 Jul;21(4):436-43. doi: 10.1111/hae.12720. Epub 2015 May 20.

PMID:
25996253
20.

Does the orphan medicinal product regulation assist or hinder access to innovative haemophilia treatment in Europe?

O'Mahony B, Peyvandi F, Bok A.

Haemophilia. 2014 Jul;20(4):455-8. doi: 10.1111/hae.12462. Epub 2014 May 8. No abstract available.

PMID:
24805888
21.

Reply to: The importance and challenge of pediatric trials of hemophilia drugs.

Peyvandi F, Rosendaal FR, O'Mahony B, Mannucci PM.

Nat Med. 2014 May;20(5):466. doi: 10.1038/nm.3551. No abstract available.

PMID:
24804749
23.

Assessment of outcomes.

Blanchette VS, O'Mahony B, McJames L, Mahlangu JN.

Haemophilia. 2014 May;20 Suppl 4:114-20. doi: 10.1111/hae.12426. Review.

PMID:
24762286
24.

Pediatric requirements in Europe stymie help for hemophilia.

Peyvandi F, Rosendaal FR, O'Mahony B, Mannuccio Mannucci P.

Nat Med. 2014 Feb;20(2):117. doi: 10.1038/nm0214-117. No abstract available. Erratum in: Nat Med. 2014 Apr;20(4):327.

PMID:
24504399
25.

The Dublin Consensus Statement 2012 on optimised supply of plasma-derived medicinal products.

O'Mahony B.

Blood Transfus. 2013 Oct;11(4):623-6. doi: 10.2450/2013.0044-13. Epub 2013 Jul 26. No abstract available.

26.

Pfizer-sponsored satellite symposium at the European Haemophilia Consortium (EHC) congress. Understanding health outcomes: focus on haemophilia.

Colvin B, Dolan G, Martinoli C, O'Mahony B.

Eur J Haematol Suppl. 2013 May;(73):1-9. doi: 10.1111/ejh.12093.

PMID:
23570445
27.

Haemophilia care in Europe - a survey of 35 countries.

O'Mahony B, Noone D, Giangrande PL, Prihodova L.

Haemophilia. 2013 Jul;19(4):e239-47. doi: 10.1111/hae.12125. Epub 2013 Apr 4.

PMID:
23557438
28.

Treatment for life for severe haemophilia A- A cost-utility model for prophylaxis vs. on-demand treatment.

Farrugia A, Cassar J, Kimber MC, Bansal M, Fischer K, Auserswald G, O'Mahony B, Tolley K, Noone D, Balboni S.

Haemophilia. 2013 Jul;19(4):e228-38. doi: 10.1111/hae.12121. Epub 2013 Mar 28.

PMID:
23534877
29.

A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries.

Noone D, O'Mahony B, van Dijk JP, Prihodova L.

Haemophilia. 2013 Jan;19(1):44-50. doi: 10.1111/j.1365-2516.2012.02934.x. Epub 2012 Aug 23.

PMID:
22913831
30.

Potentially inappropriate prescribing in older residents in Irish nursing homes.

Ryan C, O'Mahony D, Kennedy J, Weedle P, Cottrell E, Heffernan M, O'Mahony B, Byrne S.

Age Ageing. 2013 Jan;42(1):116-20. doi: 10.1093/ageing/afs068. Epub 2012 Jul 24.

PMID:
22832380
31.

Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron.

Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J.

Clin Cancer Res. 2012 May 15;18(10):2913-21. doi: 10.1158/1078-0432.CCR-11-2785. Epub 2012 Mar 27.

32.

Health technology assessment and haemophilia.

Farrugia A, O'Mahony B, Cassar J.

Haemophilia. 2012 Mar;18(2):152-7. doi: 10.1111/j.1365-2516.2012.02754.x.

PMID:
22335450
33.

Latecomers to the Electronic Health Record table.

O'Mahony B.

Ir Med J. 2011 Jun;104(6):166-7. No abstract available.

PMID:
22111390
34.

The Dublin Consensus Statement 2011 on vital issues relating to the collection and provision of blood components and plasma-derived medicinal products.

O'Mahony B, Turner A.

Vox Sang. 2012 Feb;102(2):140-3. doi: 10.1111/j.1423-0410.2011.01528.x. Epub 2011 Aug 1. No abstract available.

PMID:
21806632
35.

A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries.

Noone D, O'Mahony B, Prihodova L.

Haemophilia. 2011 Sep;17(5):e842-3. doi: 10.1111/j.1365-2516.2011.02582.x. Epub 2011 Jun 7. No abstract available.

PMID:
21649800
36.

Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.

Yubero-Lahoz S, Pardo R, Farré M, O'Mahony B, Torrens M, Mustata C, Pérez-Mañá C, Carbó ML, de la Torre R.

Clin Pharmacokinet. 2011 May;50(5):319-29. doi: 10.2165/11584550-000000000-00000.

PMID:
21456632
37.

Correlation between in vitro and in vivo erosion behaviour of erodible tablets using gamma scintigraphy.

Ghimire M, Hodges LA, Band J, Lindsay B, O'Mahony B, McInnes FJ, Mullen AB, Stevens HN.

Eur J Pharm Biopharm. 2011 Jan;77(1):148-57. doi: 10.1016/j.ejpb.2010.10.005. Epub 2010 Oct 29.

PMID:
20971189
38.

Haemophilia care in Europe: a survey of 19 countries.

O'Mahony B, Noone D, Giangrande PL, Prihodova L.

Haemophilia. 2011 Jan;17(1):35-40. doi: 10.1111/j.1365-2516.2010.02362.x. Epub 2010 Aug 16.

PMID:
20722746
39.

In-vitro and in-vivo erosion profiles of hydroxypropylmethylcellulose (HPMC) matrix tablets.

Ghimire M, Hodges LA, Band J, O'Mahony B, McInnes FJ, Mullen AB, Stevens HN.

J Control Release. 2010 Oct 1;147(1):70-5. doi: 10.1016/j.jconrel.2010.06.015. Epub 2010 Jun 23.

PMID:
20600400
40.

Personality disorders in offenders with intellectual disability: a comparison of clinical, forensic and outcome variables and implications for service provision.

Alexander RT, Green FN, O'Mahony B, Gunaratna IJ, Gangadharan SK, Hoare S.

J Intellect Disabil Res. 2010 Jul;54(7):650-8. doi: 10.1111/j.1365-2788.2010.01248.x. Epub 2010 Feb 2.

PMID:
20136682
41.

Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?

Wilson CG, O'Mahony B, Connolly SM, Cantarini MV, Farmer MR, Dickinson PA, Smith RP, Swaisland HC.

Int J Pharm. 2009 Jul 6;376(1-2):7-12. doi: 10.1016/j.ijpharm.2009.04.008. Epub 2009 Apr 14.

PMID:
19497691
42.

A pharmacoscintigraphic study of three time-delayed capsule formulations in healthy male volunteers.

McConville JT, Hodges LA, Jones T, Band JP, O'Mahony B, Lindsay B, Ross AC, Florence AJ, Stanley AJ, Humphrey MJ, Wilson CG, Stevens HN.

J Pharm Sci. 2009 Nov;98(11):4251-63. doi: 10.1002/jps.21739.

PMID:
19387976
43.

Scintigraphic evaluation of colon targeting pectin-HPMC tablets in healthy volunteers.

Hodges LA, Connolly SM, Band J, O'Mahony B, Ugurlu T, Turkoglu M, Wilson CG, Stevens HN.

Int J Pharm. 2009 Mar 31;370(1-2):144-50. doi: 10.1016/j.ijpharm.2008.12.002. Epub 2008 Dec 7.

PMID:
19114096
44.

Low dose lipid formulations: effects on gastric emptying and biliary secretion.

Kossena GA, Charman WN, Wilson CG, O'Mahony B, Lindsay B, Hempenstall JM, Davison CL, Crowley PJ, Porter CJ.

Pharm Res. 2007 Nov;24(11):2084-96. Epub 2007 Jul 27.

PMID:
17657595
45.

Nasal residence of insulin containing lyophilised nasal insert formulations, using gamma scintigraphy.

McInnes FJ, O'Mahony B, Lindsay B, Band J, Wilson CG, Hodges LA, Stevens HN.

Eur J Pharm Sci. 2007 May;31(1):25-31. Epub 2007 Feb 11.

PMID:
17368006
46.

Expanding hemophilia care in developing countries.

O'Mahony B, Black C.

Semin Thromb Hemost. 2005 Nov;31(5):561-8. Review.

PMID:
16276465
47.

WFH: back to the future.

O'Mahony B.

Haemophilia. 2004 Oct;10 Suppl 4:1-8. Review.

PMID:
15479364
48.

WFH policy on selection of coagulation factor concentrates: a rebuttal.

Giangrande P, O'Mahony B, Page D, Evatt B.

J Thromb Haemost. 2004 Jun;2(6):1023. No abstract available.

49.

Comparison of the rates of disintegration, gastric emptying, and drug absorption following administration of a new and a conventional paracetamol formulation, using gamma scintigraphy.

Kelly K, O'Mahony B, Lindsay B, Jones T, Grattan TJ, Rostami-Hodjegan A, Stevens HN, Wilson CG.

Pharm Res. 2003 Oct;20(10):1668-73.

PMID:
14620524
50.

Mercury and organochlorine content of Dipper Cinclus cinclus eggs in south-west Ireland: trends during 1990-1999.

O'Halloran J, Irwin S, Harrison S, Smiddy P, O'Mahony B.

Environ Pollut. 2003;123(1):85-93.

PMID:
12663208

Supplemental Content

Loading ...
Support Center